Integra LifeSciences Holdings Corporation (NASDAQ:IART) Position Raised by California Public Employees Retirement System

California Public Employees Retirement System raised its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 91.5% during the first quarter, Holdings Channel reports. The fund owned 121,200 shares of the life sciences company’s stock after buying an additional 57,900 shares during the period. California Public Employees Retirement System’s holdings in Integra LifeSciences Holdings Corporation were worth $5,106,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of IART. Thrivent Financial for Lutherans raised its position in shares of Integra LifeSciences Holdings Corporation by 5.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 16,080 shares of the life sciences company’s stock valued at $1,380,000 after buying an additional 860 shares during the last quarter. State Street Corp raised its position in shares of Integra LifeSciences Holdings Corporation by 6.2% in the fourth quarter. State Street Corp now owns 691,617 shares of the life sciences company’s stock valued at $59,334,000 after buying an additional 40,545 shares during the last quarter. First Mercantile Trust Co. acquired a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter valued at $279,000. Columbus Circle Investors acquired a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter valued at $18,875,000. Finally, Wells Fargo & Company MN raised its position in shares of Integra LifeSciences Holdings Corporation by 18.0% in the first quarter. Wells Fargo & Company MN now owns 2,467,892 shares of the life sciences company’s stock valued at $103,972,000 after buying an additional 375,857 shares during the last quarter. 89.74% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Holdings Corporation (NASDAQ IART) opened at 53.66 on Monday. The company’s 50-day moving average is $50.84 and its 200-day moving average is $49.46. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $54.74. The company has a market cap of $4.06 billion, a price-to-earnings ratio of 63.88 and a beta of 0.75.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its quarterly earnings data on Wednesday, April 26th. The life sciences company reported $0.39 EPS for the quarter, missing the consensus estimate of $0.40 by $0.01. The company had revenue of $258.60 million during the quarter, compared to analyst estimates of $254.19 million. Integra LifeSciences Holdings Corporation had a net margin of 6.66% and a return on equity of 16.67%. The company’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.38 EPS. On average, equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.92 earnings per share for the current year.

WARNING: This piece was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.wkrb13.com/markets/2284535/integra-lifesciences-holdings-corporation-nasdaqiart-position-raised-by-california-public-employees-retirement-system.html.

Several equities analysts recently weighed in on IART shares. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $47.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research report on Wednesday, March 22nd. ValuEngine lowered shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Jefferies Group LLC lifted their price target on shares of Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 price target on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research report on Monday, May 15th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, May 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Integra LifeSciences Holdings Corporation presently has a consensus rating of “Buy” and a consensus target price of $51.65.

In related news, Director James M. Sullivan sold 15,658 shares of the stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $45.89, for a total value of $718,545.62. Following the sale, the director now owns 70,154 shares in the company, valued at approximately $3,219,367.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Stuart Essig sold 140,000 shares of the stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $48.01, for a total value of $6,721,400.00. The disclosure for this sale can be found here. In the last three months, insiders sold 304,523 shares of company stock valued at $14,812,988. 21.40% of the stock is currently owned by insiders.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284535/integra-lifesciences-holdings-corporation-nasdaqiart-position-raised-by-california-public-employees-retirement-system.html

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.